Benefits
IBS-D and post-infectious IBS — strongest gut evidence
In post-infectious diarrhea-predominant IBS, 15 g/day (5g three times daily) over 8 weeks produced a striking effect: 79.6% of the glutamine group achieved >50-point IBS-SSS (symptom severity score) reduction vs 5.8% with placebo. Effect size is much larger than typical IBS interventions. Most relevant for IBS-D specifically (especially post-infectious onset), not all IBS subtypes. Mechanism: glutamine fuels enterocyte renewal and tight-junction protein synthesis.
Intestinal permeability — dose-dependent
Overall analysis shows NO significant effect at typical supplemental doses on gut permeability markers. Subgroup analysis: significant reduction emerges only with doses >30 g/day for durations under 2 weeks. Major implication: standard 5-10 g/day 'leaky gut' protocols are below the effective dose threshold for permeability outcomes. The exception is exercise-induced permeability, where even lower doses (~0.25 g/kg, around 17 g) attenuate the acute response.
Sickle cell disease — FDA-approved indication
L-glutamine (branded as Endari®) is FDA-approved for sickle cell disease in patients ≥5 years old. At 0.3 g/kg twice daily over 48 weeks, it reduced sickle cell crises by 25% (3.0 vs 4.0 events/year), hospitalizations by 33% (2.0 vs 3.0), and shortened hospitalization duration vs placebo. Mechanism: glutamine supports NAD+/NADH redox balance in red blood cells, reducing oxidative damage and sickling triggers.
Critical illness — caution required
A large trial in 1,223 mechanically ventilated critically ill patients found that high-dose glutamine combined with antioxidants increased 28-day mortality (32.4% vs 27.2%). This reset prior enthusiasm for routine glutamine in ICU patients. European and American guidelines now caution against parenteral glutamine in shock and multi-organ failure. Specific scenarios (burns, short bowel syndrome) retain enteral glutamine indications.
Athletic recovery — overrated in marketing
Despite heavy marketing for muscle recovery, the trial evidence is weak. Multiple analyses find inconsistent effects on muscle soreness, performance, or recovery markers in healthy athletes. Glutamine stores in muscle are typically maintained adequately by dietary protein in well-fed athletes. The more plausible benefit is protection against exercise-induced gut permeability — particularly relevant for endurance athletes prone to GI distress during training.
Chemotherapy mucositis and short bowel syndrome
Established clinical applications in oncology supportive care. Glutamine reduces severity of chemotherapy-induced oral mucositis and improves enterocyte turnover after intestinal resection. Used in specialized rehydration solutions for short bowel syndrome where its dual role (sodium cotransport substrate + enterocyte fuel) is uniquely valuable. Tumor-cell-uptake concerns (theoretical 'feeding cancer') are generally not supported by clinical data.
Wound healing and surgical recovery
Multiple trials in burn patients and major surgical populations show glutamine supplementation accelerates wound healing, supports collagen synthesis, and reduces infection rates. Enteral glutamine has stronger evidence than parenteral in non-critical-illness contexts. A reasonable component of nutrition support in surgical and burn care; not validated for cosmetic wound healing in otherwise healthy adults.
Sodium cotransport and oral rehydration
Glutamine functions as a sodium cotransport substrate in the small intestine, supporting fluid absorption parallel to glucose-mediated SGLT1. Glutamine-based oral rehydration solutions produced sodium and water absorption comparable to WHO standard in cholera-toxin animal models. Pediatric diarrhea trials vs WHO-ORS have been mixed. Specialized application in short bowel syndrome rehydration where the dual mechanism matters.
Mechanism of action
Primary fuel for enterocytes
Glutamine supplies 60-70% of energy for small intestinal epithelial cells (enterocytes), which turn over every 3-5 days. It's the single most important nutrient for maintaining intestinal barrier integrity. Enterocytes preferentially metabolize glutamine over glucose. This is the molecular basis for the gut-related clinical applications.
Conditionally essential under stress
Endogenous glutamine synthesis (primarily skeletal muscle) typically meets demand. During catabolic stress — sepsis, burns, major surgery, prolonged intense exercise — demand exceeds production, depleting muscle and plasma glutamine pools. Supplementation rationale strongest in these stress states; less clear in healthy adults at rest.
Immune cell substrate
Lymphocytes, macrophages, and neutrophils require glutamine at rates similar to glucose. Glutamine availability affects T-cell proliferation, cytokine production, and phagocytic function. Mechanism behind clinical utility in critical illness and post-surgical infection prevention.
Nitrogen carrier and acid-base balance
Glutamine is the major non-toxic transport form for nitrogen between tissues. Renal glutamine catabolism produces ammonia for excretion, contributing to acid-base homeostasis. Plays key role in interorgan amino acid metabolism.
Sickle cell redox protection
Glutamine supports NAD+/NADH balance in red blood cells, reducing oxidative damage that triggers sickling. Mechanism behind FDA-approved Endari® indication. Sickle cells have reduced glutamine uptake capacity, making supraphysiologic doses necessary for therapeutic effect.
Clinical trials
Double-blind randomized placebo-controlled trial of oral L-glutamine for post-infectious diarrhea-predominant IBS. Outcomes measured via the IBS Symptom Severity Score (IBS-SSS) — a validated, well-established instrument with a >50-point reduction threshold for clinically meaningful improvement. Published in the journal Gut.
106 patients with post-infectious diarrhea-predominant IBS. 8-week intervention.
L-glutamine 5 g three times daily (15 g/day total) over 8 weeks produced a 79.6% responder rate (>50-point IBS-SSS reduction) vs only 5.8% with placebo — a striking effect size compared to most IBS interventions. The trial established post-infectious IBS-D as the strongest indication for glutamine in gut disorders and supported the biological plausibility that supplementation supports enterocyte renewal.
Evidence review and pooled analysis of clinical trials evaluating L-glutamine supplementation for intestinal permeability outcomes (the 'leaky gut' framework). Included trials assessed permeability via lactulose-mannitol ratio or related markers. Published in Amino Acids. Subgroup analyses by dose, duration, and population.
Multiple trials across various adult populations. Doses ranging from typical supplemental (5-10 g/day) to high-dose clinical use (>30 g/day).
Overall analysis showed NO significant effect on permeability at typical supplemental doses (WMD -0.00, 95% CI -0.04 to 0.03). Subgroup analysis identified a significant effect only at doses >30 g/day for short durations (<2 weeks). Major practical implication: standard 5-10 g/day 'leaky gut' protocols are below the effective dose threshold demonstrated for permeability outcomes.
Phase 3 randomized double-blind placebo-controlled trial supporting FDA approval of L-glutamine (Endari®, Emmaus Medical) for sickle cell disease in 2017. Primary outcome: number of pain crises. Secondary outcomes: hospitalizations, acute chest syndrome, hospital length of stay. Published in NEJM.
230 patients ≥5 years old with sickle cell anemia or sickle β⁰-thalassemia. 48-week intervention.
L-glutamine 0.3 g/kg twice daily reduced median sickle cell crises by 25% (3.0 vs 4.0 events/year), hospitalizations by 33% (2.0 vs 3.0), and shortened hospitalization duration vs placebo. Effects emerged across the 48-week protocol. Foundation for FDA approval and current clinical use as a daily disease-modifying therapy in sickle cell disease.
Large multicenter randomized controlled trial evaluating high-dose glutamine and antioxidants in mechanically ventilated critically ill patients. 2×2 factorial design with parenteral and enteral glutamine supplementation. Primary outcome: 28-day mortality. Published in NEJM. Conducted across multiple ICUs in North America and Europe.
1,223 mechanically ventilated critically ill adults across multiple ICUs. ICU-stay-duration intervention.
Surprisingly, high-dose glutamine + antioxidants increased 28-day mortality (32.4% vs 27.2%, p=0.05) compared to placebo. This finding reset prior enthusiasm for routine glutamine in critical care. European and American guidelines now caution against parenteral glutamine specifically in shock and multi-organ failure. Specific scenarios (burns, short bowel syndrome) retain enteral glutamine indications.
Dose-response study evaluating oral L-glutamine for prevention of exercise-induced intestinal permeability — a known issue in endurance athletes that contributes to GI distress and 'leaky gut' biomarkers during prolonged exercise. Permeability assessed via lactulose-rhamnose or related dual-sugar absorption methods.
Trained athletes performing prolonged or heat-stressed exercise protocols. Acute pre-exercise dosing.
Even relatively low doses (~0.25 g/kg, roughly 17 g for a 70 kg adult) attenuated exercise-induced intestinal permeability vs placebo. Useful evidence that the very-high-dose threshold for permeability outcomes in the broader pooled analysis doesn't necessarily apply in the specific context of exercise-stress permeability — which may be more responsive to acute dosing strategies.